Trials / Withdrawn
WithdrawnNCT05700734
MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)
A Single-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-retroviral Activity of MK-8510 Monotherapy in Anti-retroviral-naïve HIV-1 Infected Participants
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and anti-retroviral activity of MK-8510 monotherapy in anti-retroviral-naïve HIV-1 infected participants.
Conditions
- HIV-1
- Human Immunodeficiency Virus 1
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-8510 | Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg. |
Timeline
- Start date
- 2023-04-17
- Primary completion
- 2024-02-14
- Completion
- 2024-02-14
- First posted
- 2023-01-26
- Last updated
- 2023-03-27
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05700734. Inclusion in this directory is not an endorsement.